Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Dizal Approved to Launch EGFR Inhibitor for NSCLC with Exon 20 Mutations

publication date: Aug 23, 2023

Shanghai Dizal Pharma announced its lead drug, sunvozertinib, was approved for China use as a second line therapy for locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations. Patients must have progressed following platinum-based chemotherapy. Sunvozertinib is an irreversible EGFR inhibitor discovered by Dizal that targets a wide spectrum of EGFR mutations with wild-type EGFR selectivity. Dizal was formed as a JV with AstraZeneca complete with AstraZeneca assets after the company closed its Shanghai R&D Center. More details....

Stock Symbol: (SHA: 688192)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital